The abnormal expression of RBM10 was closely linked to the prognosis value, genetic mutation, tumor immune microenvironment, immune regulation, TMB, and MSI of various human different cancers, which strongly indicate that RBM10 could be served as a potential biomarker for cancer prognosis and immunotherapy response. The gene discussed is RBM10; the disease is neoplasm.